TWO · 7561.TWO
Bioray Biotech Co., Ltd
NT$17.25-NT$0.60 (-3.36%)
Bioray Biotech Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 33.91% below the high.
Loading market information…
TWO · 6621.TWO · TWD
Stock price
Quote as of Oct 30, 2026, 06:22 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
UniPharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
UniPharma Co., Ltd. is a Taiwanese enterprise specializing in the distribution of pharmaceuticals, medical apparatus, and diagnostic kits. Its diagnostic portfolio encompasses various medical disciplines, including oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company's offerings feature products such as Adept reduction solution, anesthetic injections (including bain, esmolol HCI, and naloxone), the Elisa DR-70 test for in-vitro tumor detection, and Fomeject antidote injections. Furthermore, UniPharma extends its services to include drug development, research and development, clinical studies, and marketing. Its client base includes major medical centers, regional hospitals, and local clinics. Founded in 1998, UniPharma is headquartered in Taipei, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$17.25-NT$0.60 (-3.36%)
Bioray Biotech Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 33.91% below the high.
NT$9.72+NT$0.15 (+1.57%)
Health & Life Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.97% below the high.
NT$11.70+NT$2.40 (+25.81%)
DuoGenic StemCells corporation’s quoted price sits in the lower half of its reported 52-week range, 45.58% below the high.
NT$6.97-NT$0.23 (-3.19%)
Sunder Biomedical Tech. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.4% below the high.
NT$29.90-NT$0.60 (-1.97%)
A-SPINE Asia Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.17% below the high.
NT$7.78+NT$0.33 (+4.43%)
Pharmigene, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.35% below the high.
NT$16.60-NT$0.60 (-3.49%)
Welgene Biotech Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.43% below the high.
NT$14.40+NT$0.35 (+2.49%)
EPS Bio Technology Corp.’s quoted price sits in the lower half of its reported 52-week range, 22.16% below the high.
